The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Tree shaking going to take out the weak investors again. Hold for Nano gold.
NHS have been paying £5 per mask, check the news.
The Biden administration will give away 400 million.
https://www.nytimes.com/live/2022/01/19/world/omicron-covid-vaccine-tests#covid-biden-free-masks-n95-tests
A big order from US could me this baby move fast. Buyers are flooding in now.
A bid order from US could me this baby move fast. Buyers are flooding in now.
"Biden promises free masks in the ‘largest deployment"
US urgently need Pro-Larva Covid killing masks
"Biden promises free masks in the ‘largest deployment"
US urgently need Pro-Larva Covid killing masks
https://twitter.com/mohamme25312926
The Biden administration will give away masks in the ‘largest deployment’ of such equipment in U.S. history.
https://twitter.com/mohamme25312926/status/1483909479343263753
Omega will look to raise funds to drive growth as and when appropriate.!!!!!!
How long before placing?????
This might head to 5p now.
This is reason why it has taken 2 years. NHS Procurement pilot.
https://twitter.com/mohamme25312926/status/1483154247076175877
VOLZ JV - NHS CONTRACT -
Why would Volz set-up a company same day as £5 Billion pound contract is issued?
Why call Nanosynth (Medical) Limited?
https://twitter.com/mohamme25312926/status/1483161616116076546
The Company is pleased to announce that the 5-ply version of its Pro-Larva anti-viral mask, developed with Volz Filters UK Ltd ("Volz"), has been approved by the UK's Medicines and Healthcare products Regulatory Agency ("MHRA"). The 5-ply mask has an additional filter layer, produced by Volz, after the hydrophobic outer layer, further strengthening the mask's already excellent bacterial filter efficiency.
The last year has established a close working relationship between Volz and the Company's subsidiary, Pharm 2 Farm Ltd ("P2F"). Not only is Volz manufacturing the existing 4-ply anti-viral masks for P2F, but the two companies have also been working on developing a new anti-viral filter material, as an extension of the work on the anti-viral mask and covered by the same patent. This new material has passed the proof-of-concept stage and Volz and P2F are now looking at how this could be commercialised (for example, in heating, ventilation and air conditioning systems), although this is expected to take several months, with work required on moving from proof-of-concept to large scale production.
"Volz have been an excellent partner to Pharm 2 Farm, providing support in a number of areas. We are delighted with the MHRA approval for the 5-ply mask and to be working with Volz on an exciting development of the a-virion technology, with the potential to incorporate it into air filters."
It's glaringly obvious that the new state of the art uk manufacturing facility will be set up to support such contracts. As mentioned in the proactive interview and strategic update by CEO Mark Duffin.
Expect all to be revealed very soon!
Why go out of your way to get it Approved as a Class 1 medical device? To sell to NHS
Approved as a Class 1 medical device by the Medicines and Healthcare products Regulatory Agency ("MHRA")
The worlds first and only MHRA approved anti-viral mask
Also, anti-viral. Anti-viral cleaning products are being used in hospitals and care homes instead of anti-bac now! Anti-viral will become the new norm. They just need to catch up and we will be sitting waiting with anti-viral everything MHRA approved
VOLZ JV - NHS CONTRACT -
Why would Volz set-up a company same day as £5 Billion pound contract is issued?
DR Cave mentions NHS in the interview. The delay could be due to below timeline.
The Company is pleased to announce that the 5-ply version of its Pro-Larva anti-viral mask, developed with Volz Filters UK Ltd ("Volz"), has been approved by the UK's Medicines and Healthcare products Regulatory Agency ("MHRA"). The 5-ply mask has an additional filter layer, produced by Volz, after the hydrophobic outer layer, further strengthening the mask's already excellent bacterial filter efficiency.
https://twitter.com/mohamme25312926/status/1483186674700103682
VOLZ JV - NHS CONTRACT -
Why would Volz set-up company same day as £5 Billion pound contract is issued?
https://twitter.com/mohamme25312926/status/1483161616116076546
Why I think NHS Contract is due soon.
https://twitter.com/mohamme25312926/status/1483154247076175877
https://twitter.com/mohamme25312926/status/1483147111642419201
Sensyne Health: what does it do?
In a nutshell, Sensyne Health is an AIM-listed healthcare company that uses artificial intelligence to analyse data. The company operates two divisions — Discovery Sciences and Software Products.
I’ll explain each of these businesses in turn.
Discovery Sciences
I should highlight that over 80% of revenue is generated from the Discovery Sciences division. This is where it analyses anonymised patient data from NHS trusts using machine learning (a subset of artificial intelligence). So I like the stock because the analysis can be used to improve pharmaceutical development, increase the understanding of diseases and advance clinical design trials.
One reason I’m excited about this UK small-cap stock is that this division bridges the gap between the NHS and the pharmaceutical industry. The NHS has been busy converting its paper files into digital records. And in my opinion, the NHS has the data but has limited resources to analyse it. Pharmaceutical companies are likely to welcome a company that has already done the number crunching and can offer both scientific value and a financial return.
Software Products
While the Software Products business is small, I think it has huge growth potential. Sensyne Health develops digital health products that help clinicians with patient care. These digital products also generate data, which the company can use for research.
I think division is a key growth driver. Some of Sensyne Health’s products enable clinicians to remotely monitor and manage diabetes and blood pressure during pregnancy. I reckon if this is successful, these products could be rolled out to the wider patient community, thereby increasing revenue potential.
I also like that the firm is collecting data from its products. This means that it’ll be able to analyse it and sell the scientific value it creates to pharmaceutical companies.
https://twitter.com/mohamme25312926/status/1481313908157816833
Just Keep loading the MMs are taking out weak investors. (Bed Wetters)
https://twitter.com/mohamme25312926/status/1481605972372201473